Sugi Predict

Sugi Predict / Compounds / SCHEMBL4346832

SCHEMBL4346832

SCHEMBL4346832

COc1cc([N+](=O)[O-])c(NC(C)=O)cc1Br

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAPT P10636 4/20 0.49
▸ KMT2A Q03164 3/20 0.49
▸ POLB P06746 2/20 0.49
▸ MEN1 O00255 2/20 0.49
▸ NPSR1 Q6W5P4 2/20 0.48
▸ ABCB1 P08183 3/20 0.46
▸ ABCC1 P33527 3/20 0.46
▸ HTT P42858 2/20 0.46
▸ ALDH1A1 P00352 2/20 0.45
▸ LMNA P02545 2/20 0.45
▸ GALR2 O43603 1/20 0.45
▸ MITF O75030 1/20 0.45
▸ HSP90AA1 P07900 1/20 0.45
▸ HPGD P15428 1/20 0.45
▸ XBP1 P17861 1/20 0.45
▸ CCR6 P51684 1/20 0.45
▸ SMN1; SMN2 Q16637 1/20 0.45
▸ PKM P14618 1/20 0.43
▸ THRB P10828 1/20 0.43
▸ GAA P10253 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29447084 1.00 MAPT (0.49) MAPTKMT2APOLBMEN1NPSR1
SCHEMBL1511509 0.94 MAPT (0.49) MAPTKMT2APOLBMEN1NPSR1
SCHEMBL28689986 0.89 MAPT (0.49) MAPTKMT2APOLBMEN1NPSR1
SCHEMBL9396485 0.88 MAPT (0.52) MAPTKMT2APOLBMEN1NPSR1
SCHEMBL28664013 0.87 MAPT (0.51) MAPTKMT2APOLBMEN1NPSR1
SCHEMBL7653533 0.85 MAPT (0.55) MAPTKMT2APOLBMEN1NPSR1
SCHEMBL5953169 0.84 KMT2A (0.50) MAPTKMT2APOLBMEN1NPSR1
SCHEMBL13811009 0.84 NPSR1 (0.49) MAPTKMT2APOLBNPSR1ABCB1
SCHEMBL4857875 0.84 MAPT (0.44) MAPTKMT2APOLBMEN1NPSR1
SCHEMBL1646147 0.83 MAPT (0.48) MAPTKMT2APOLBMEN1NPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12509460-B2 Methods and compositions for modulating splicing SKYHAWK THERAPEUTICS, INC. (US) 2025-12-30 — — US disclosed
US-20230020922-A1 METHODS AND COMPOSITIONS FOR MODULATING SPLICING SKYHAWK THERAPEUTICS, INC. 2023-01-19 — — US disclosed
CN-114126613-A Methods and compositions for modulating splicing 斯基霍克疗法公司 2022-03-01 — — CN disclosed
EP-3920926-A1 METHODS AND COMPOSITIONS FOR MODULATING SPLICING Skyhawk Therapeutics, Inc. (US) 2021-12-15 — — EP disclosed
WO-2020163541-A1 METHODS AND COMPOSITIONS FOR MODULATING SPLICING SKYHAWK THERAPEUTICS, INC. (US) 2020-08-13 — — WO disclosed
US-9725465-B2 Biaryl acetamide compounds and methods of use thereof AMBIT BIOSCIENCES CORPORATION (US) 2017-08-08 — — US disclosed
US-9725465-B2 Biaryl acetamide compounds and methods of use thereof AMBIT BIOSCIENCES CORPORATION (US) 2017-08-08 — — US disclosed
EP-1606268-B1 5,10-DIHYDRO-11H-DIBENZO[B,E][1,4]DIAZEPIN-11-ONE AS KINASE INHIBITORS ABBVIE INC (US) 2015-05-20 — — EP disclosed
US-20150065468-A1 BIARYL ACETAMIDE COMPOUNDS AND METHODS OF USE THEREOF AMBIT BIOSCIENCES CORP (US) 2015-03-05 — — US disclosed
US-8809368-B2 Compounds affecting gap junction activity KANSAS STATE UNIVERSITY RESEARCH FOUNDATION (US) 2014-08-19 — — US disclosed
US-8809368-B2 Compounds affecting gap junction activity KANSAS STATE UNIVERSITY RESEARCH FOUNDATION (US) 2014-08-19 — — US disclosed
US-20090143425-A1 COMPOUNDS AFFECTING GAP JUNCTION ACTIVITY KANSAS STATE UNIVERSITY RESEARCH FOUNDATION (US) 2009-06-04 — — US disclosed
US-20090143425-A1 COMPOUNDS AFFECTING GAP JUNCTION ACTIVITY KANSAS STATE UNIVERSITY RESEARCH FOUNDATION (US) 2009-06-04 — — US disclosed
US-7456169-B2 Heterocyclic kinase inhibitors ABBOTT LABORATORIES INC. (US) 2008-11-25 — — US disclosed
WO-2007127930-A2 COMPOUNDS AFFECTING GAP JUNCTION ACTIVITY KANSAS STATE UNIVERSITY RESEARCH FOUNDATION (US) 2007-11-08 — — WO disclosed
WO-2007127930-A2 COMPOUNDS AFFECTING GAP JUNCTION ACTIVITY KANSAS STATE UNIVERSITY RESEARCH FOUNDATION (US) 2007-11-08 — — WO disclosed
US-20070254867-A1 Heterocyclic Kinase Inhibitors ABBVIE INC. 2007-11-01 — — US disclosed
EP-1606268-A1 HETEROCYCLIC KINASE INHIBITORS Abbott Laboratories (US) 2005-12-21 — — EP disclosed
US-20040254159-A1 Heterocyclic kinase inhibitors ABBOTT LABORATORIES 2004-12-16 — — US disclosed
WO-2004076424-A1 HETEROCYCLIC KINASE INHIBITORS ABBOTT LABORATORIES (US) 2004-09-10 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230020922-A1 METHODS AND COMPOSITIONS FOR MODULATING SPLICING RBM17, SF3B1, SNRPA1 MAPT 2405/4885KMT2A 2256/4885POLB 662/4885
US-12509460-B2 Methods and compositions for modulating splicing SF3B1, RTCB, RBM17 MAPT 4636/4885KMT2A 2279/4885POLB 562/4885
US-20040254159-A1 Heterocyclic kinase inhibitors MAP3K20, MAP3K19, MAP3K1 MAPT 4057/4885KMT2A 1398/4885POLB 2556/4885
US-20090143425-A1 COMPOUNDS AFFECTING GAP JUNCTION ACTIVITY GJB2, GJA1, GAP43 MAPT 2537/4885KMT2A 4622/4885POLB 3424/4885
US-20150065468-A1 BIARYL ACETAMIDE COMPOUNDS AND METHODS OF USE THEREOF ERBB2, ERBB3, AADAC MAPT 2862/4885KMT2A 1471/4885POLB 2281/4885
US-20070254867-A1 Heterocyclic Kinase Inhibitors MAP3K20, MAP3K19, MAP4K2 MAPT 3753/4885KMT2A 1376/4885POLB 1933/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.